Clostridium Difficile Clinical Trial
Official title:
A Comparison of Efficacy of Fresh Versus Frozen Donor Stool for Fecal Microbial Transplant in Children With Recurrent Clostridium Difficile Infections
The primary goal of this study will be to assess whether stool collected and frozen from
anonymous screened unrelated donors can be as effective as stool freshly collected from
recipient's parents when used in Fecal Microbial Transplant for the eradication of recurrent
Clostridium difficile infections in children. In the current protocols, which are more than
90% effective, each child who is receiving a fecal transplant has to provide their own donor
stool, usually from a parent or close relative. This requires considerable screening costs
for each case and is logistically complicated as the donor must be present and must stool
just prior to the transplant. The investigators hope to show that a small number of healthy
donors can provide stool samples which can be frozen and banked and then thawed for use in
numerous patients. The primary goal is to show that Clostridium difficile will be eradicated
as effectively (Greater than 90% success) when using the stool from the frozen donors.
The study will also evaluate the inflammatory response and intestinal microbiome in young
children aged 1-3 years with Clostridium difficile infections to better predict which ones
will respond to fecal transplantation and which ones have incidental infections. For this
question the investigators will gather stool samples to check for lactoferrin, calprotectin,
and alpha1antitrypsin, and 16s ribosomal RNA analysis in children before and after the fecal
transplants. The goal is to see if there is an intestinal microbiome that predisposes some
children to getting sick from Clostridium difficile versus just having it incidentally.
The study is designed to enroll forty children aged 1-18 with recurrent Clostridium difficile
Infection (CDI). Recurrent CDI is defined as an infection that persists after three rounds of
appropriate antibiotics. Enrollees will be randomly assigned to receive Fecal Microbial
Transplant using stool from either a screened relative as per current protocols versus using
frozen stool that has been collected from healthy volunteers.
Primary outcome will be the eradication of the Clostridium difficile as defined by
elimination of diarrhea with a negative Clostridium difficile toxin stool test.
Secondary outcomes will include a measure of quality of life pre and post Fecal Microbial
Transplant using a validated quality of life survey instrument, the Health Act Child Health
Questionnaire. The investigators will also assess for inflammation in the stool using
lactoferrin and calprotectin and evaluate the stool microbiome in recipients pre and post
transplant using sequencing to look for any pattern that predicts successful eradication.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02896244 -
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
|
||
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Recruiting |
NCT01973465 -
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
|
N/A | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT01066221 -
Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile
|
N/A | |
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
Completed |
NCT02857582 -
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
|
Phase 2 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT01703494 -
Fecal Transplant for Relapsing C. Difficile Infection
|
Phase 2 | |
Completed |
NCT01813500 -
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01087892 -
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection
|
N/A | |
Suspended |
NCT00591357 -
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
|
Phase 4 | |
Recruiting |
NCT00377078 -
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
|
N/A | |
Completed |
NCT02254967 -
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
|
Phase 4 | |
Terminated |
NCT01775397 -
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
|
Phase 4 | |
Terminated |
NCT03617172 -
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
|
Phase 2 | |
Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
Completed |
NCT02437487 -
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
|
Phase 2 |